ivana magovcevicliebisch phd jd  axcella health inc  skip to main content menu search this site what we dowhy amino acidsour platformtherapeutic focuswho we areleadership teamboard of directorsadvisorsinvestorspress releases  eventsjoin uscareer opportunities ivana magovcevicliebisch phd jd executive vice president chief strategy and corporate development officer   dr ivana magovcevicliebisch has more than  years of senior management experience in biotechnology and pharmaceutical industry with expertise in financing corporate partnering and ma clinical development regulatory affairs commercialization legal and ip matters and preparation and implementation of operating plansprior to joining axcella dr magovcevicliebisch was senior vice president and head of global business development at teva pharmaceuticals industries ltd in her time at teva dr magovcevicliebisch led and executed over  billion in business development transactions including licensing and acquisition of companies businesses commercial products drug candidates andor technologies as well as asset divestitures to support operational strategies and objectives of teva’s global specialty rd and commercial franchises to drive growth and value for the companydr magovcevicliebisch began her biopharma career at transkaryotic therapies inc where she was director of intellectual property and patent counsel subsequently dr magovcevicliebisch joined dyax corp and served in management roles of increasing scope and responsibility including executive vice president and chief operating officer she established the commercial infrastructure of the company’s first fdaapproved drug kalbitor® for treatment of hereditary angioedema attacks a very rare and potentially lifethreatening genetic conditiondr magovcevicliebisch currently serves as a member of the board of directors of applied genetic technologies corporation agtc a biotech company developing cures for rare eye diseases through gene therapy a member of the board of directors for alivio therapeutics a biotech company developing novel drug formulations for inflammatory diseases a trustee of the wentworth institute of technology and an overseer of the boston ballet boston museum of science and beth israel deaconess medical centerdr magovcevic holds a phd in genetics from harvard university and received her jd in high technology law from suffolk university law school she graduated from wheaton college with a ba in biology and chemistry in  dr magovcevicliebisch was the winner of the woman entrepreneurs in science and technology leadership award what drew you to axcellathe opportunity to be a member of an exceptional team working together to improve lives of patients and their families through a revolutionary technologyyour greatest nonprofessional accomplishmentbeing a mother to two amazing kidsas a child what did you want to be when you grew upa fashion designerwhat do you know now that your wish you knew when you were youngerthe importance of worklife balance – this is such an important part of the culture at axcellafavorite book and authorone hundred years of solitude by gabriel garcía márquez back to leadership team contact us  memorial drive cambridge ma entrance on blackstone street  third flooro   f infoaxcellahealthcom linkedin site mapterms of useprivacy policy   axcella health inc all rights reserved ivana magovcevic‐liebisch phd jd — alivio ivana magovcevic‐liebisch phd jd dr ivana magovcevicliebisch is senior vice president and head of global business development at teva pharmaceuticals in this capacity ivana is responsible for the execution of transactions identified by teva’s rd global franchises and us specialty teams including the licensing of commercial products drug candidates and technologies prior to teva dr magovcevicliebisch held several senior positions at dyax corp most recently as executive vice president and chief operating officer prior to dyax dr magovcevicliebisch was director of intellectual property and patent counsel for transkaryotic therapies inc cambridge ma  back ivana magovcevicliebisch phd jd  the conference forum chief medical officer summit save the date may   omni parker house boston ma usa menu home conferences mobile in clinical trialsdpharm precon workshopdisruptive innovations uspartnerships in drug deliverypatients as partners europedisrupting clinical trials europeimmunooncology °rd leadership summitpatients as partners usclinical trial collaborationsclinical research as a care optionchief medical officer summitrational combinations ° advisors scholarships pharma talk radio about us affiliations cancer research institute ciscrp mission faqs news videos contact us how to get involved exhibitsponsor speakerpanelist media overview speakers speaker presentations agenda download agenda who should attend sponsorshipexhibitor opportunities  sponsors  exhibitors  sponsors  exhibitors  partners  media venue  hotel information event blog  photo gallery scholarships chief medical officer summit speakers ivana magovcevicliebisch phd jd svp head of corporate business development teva pharmaceuticals ivana magovcevicliebisch joined teva as senior vice president head of global business development in april  in this capacity ivana is responsible for the execution of transactions identified by teva’s rd global franchises and us specialty teams including the licensing of commercial products drug candidates and technologies prior to teva dr magovcevicliebisch joined dyax corp in april  and had served as an executive officer at the company since  during her tenure she held several senior positions within the company most recently as executive vice president and chief operating officer prior to dyax dr magovcevicliebisch was director of intellectual property and patent counsel for transkaryotic therapies inc cambridge ma she received her jd in high technology law from suffolk university law school boston ma and her phd in genetics from harvard university cambridge ma return to speakers page » home  conferences  advisors  news  about us  contact us privacy policy  terms and conditions   the conference forum follow us facebook twitter linkedin ivana magovcevicliebisch phd jd executive profile  biography  bloomberg july    am et pharmaceuticals company overview of axcella health inc snapshotpeople  overviewboard memberscommittees executive profile ivana magovcevicliebisch phd jdchief strategy  corporate development officer and executive vice president axcella health incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr ivana magovcevicliebisch phd jd has been chief strategy  corporate development officer and executive vice president at axcella health inc since may   dr magovcevicliebisch served as the head of corporate business development and senior vice president of teva pharmaceutical industries limited since april  dr magovcevicliebisch was responsible for the execution of transactions identified by teva’s rd global franchises and us specialty teams  including the licensing of commercial products drug candidates and technologies she served as an advisor of puretech health plc from october   to april   she served as the chief operating officer of dyax corp from august  to march   and executive vice president from june  to march   she served as the chief business officer of dyax corp from june  to august  chief legal officer since february  and as its general counsel from december   to august  she served as an executive vice president of corporate development at dyax corp since september  executive vice president of administration since april  and also served as its assistant secretary she headed the legal and investor relations  corporate communications departments at dyax dr magovcevicliebisch served as the chief patent counsel and senior vice president of legal affairs at dyax corp from february  to december   and also served as its executive vice president of corporate communications since december   she joined dyax corp in april  as vice president of intellectual property she is also a trustee of the wentworth institute of technology and an overseer of the boston ballet boston museum of science and beth israel deaconess medical center dr magovcevicliebisch served as director of intellectual property and patent counsel of transkaryotic therapies inc from  to  she served as a patent agent of fish and richardson and lahive  cockfield two boston patent law firms she has been a director at applied genetic technologies corporation since june   she holds a phddoctorate degree in genetics from harvard university and a jd from suffolk universityread full background corporate headquarters  memorial drivecambridge massachusetts united statesphone fax  board members memberships presentdirectorapplied genetic technologies corporation education doctorate harvard universityjd suffolk university other affiliations dyax corpharvard universityteva pharmaceutical industries limitedsuffolk universityapplied genetic technologies corporationpuretech health plc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact axcella health inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close ivana magovcevic  waban ma  intelius sign in we found ivana magovcevic in waban ma ivana magovcevic intelius found that ivana magovcevic is a female between  and  years old from waban ma we have connected them to  addresses  phones and  relatives or associates also known as ivana maravic magovcevic ivana maravic magovcevicliebisch ivana maravicmagovcevic magovcevic ivana maravic maravic magovcevic ivana ivana liebisch get report now age ivana magovcevic is in her s ivana has lived in waban ma boston ma cambridge ma ivanas relatives lars liebisch katica magovcevic mariola magovcevic ivana magovcevic zodiac signcancer genderfemale professional status general counsel at dyax corp get report now want to know more about ivana get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about ivana or use our people search engine to find others get background check on ivana magovcevic get a criminal check on ivana magovcevic get a public record report on ivana magovcevic get a people search report on ivana magovcevic ivana magovcevics contact information known cities lived in find out where ivana magovcevic has lived as well as ivana magovcevics phone numbers and email addresses ivana magovcevic has lived in  states massachusetts address for ivana magovcevic  c r waban ma has lived in waban ma boston ma get full address report phone numbers associated with ivana magovcevic    waban ma    brookline ma    brookline ma get full phone report email addresses associated with ivana magovcevic get email report ivana magovcevics professional information information regarding ivana magovcevics professional history find out previous places ivana magovcevic has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act ivana magovcevic has worked at  places company dyax corp title general counsel company dyax corp title executive vice president ivana magovcevics experience title general counsel company dyax corp job details dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs dyax is developing dx a fully human monoclonal antibody for the prevention of hae attacks additionally dyax markets kalbitor â® ecallantide for the treatment of acute attacks of hae in patients  years of age and older both dx and kalbitor were identified using dyaxâ€™s proprietary phage display technology dyax has broadly licensed this technology under its licensing and funded research portfolio lfrp the current portfolio includes two fda approved products and multiple product candidates in various stages of clinical development for which dyax is eligible to receive future milestones and royalties title executive vice president company dyax corp job details additional professional information on ivana magovcevic see ivana magovcevics linkedin profile ivana magovcevics social network and potential email matches find out potential social network profiles and potential email usernamed for ivana magovcevic ivana magovcevics known social networks and potential email matches find all of ivana magovcevics social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches ivana magovcevic username matches ivanamagovcevic magovcevicivana ivanamagovcevic magovcevicivana ivanamagovcevic magovcevicivana ivanamagovcevic magovcevicivana imagovcevic popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches i magovcevic intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors nasdaqagtc facebook google linkedin twitter email rss jun   « previous release  next release » pdf agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors gainesville fla june   globe newswire  applied genetic technologies corporation nasdaqagtc a clinical stage biotechnology company developing adenoassociated virus aavbased gene therapies for the treatment of rare eye diseases today announced that it has appointed david r guyer md and ivana magovcevicliebisch phd jd to the companys board of directors dr guyer and dr magovcevicliebisch bring important expertise and industry leadership to the agtc board of directors and i expect that both will be instrumental to our success in realizing the potential of our bestinclass technology and product portfolio said dr scott koenig md chairman of the agtc board of directors we believe that the combination of davids significant track record in developing and commercializing ophthalmologic therapies with ivanas extensive experience in biopharmaceutical business development and operations will prove a powerful asset for agtc as we advance our genebased product candidates for genetic eye diseases i am pleased to welcome them to the agtc board of directors dr guyer is cofounder chief executive officer and chairman of the board of ophthotech corporation under his leadership ophthotech has successfully completed several rounds of private and public financing and entered into an exus licensing and commercialization deal for fovista® with novartis that is one of the largest exus partnering transactions in the biotechnology industry previously dr guyer cofounded and served as ceo and director at eyetech pharmaceuticals inc where he oversaw the rapid development and successful commercialization of macugen® pegaptanib sodium the first fdaapproved antivegf pharmacological treatment for wet amd dr guyer also was a venture capitalist and partner at sv life sciences and has served on multiple boards of both public and private companies dr guyer received his bs from yale college summa cum laude and his md from the johns hopkins university school of medicine he completed his ophthalmology residency at the wilmer ophthalmological institute at johns hopkins hospital and a retinal fellowship at the massachusetts eye and ear infirmary at harvard medical school agtcs proprietary aav platform has tremendous potential to address substantial unmet medical need i welcome the opportunity to join agtcs board of directors and look forward to working with the companys leadership to realize the full potential of the aav platform and to improve the care and outcomes for patients noted dr guyer as senior vice president head of global business development for teva pharmaceutical industries ltd since april  dr magovcevicliebisch is responsible for the execution of transactions identified by tevas rd global franchises and us specialty teams including the licensing andor acquisition of commercial products drug candidates and technologies prior to teva dr magovcevicliebisch served as an executive officer of dyax corp during her twelveyear tenure she held several senior positions within the company most recently serving as executive vice president and chief operating officer at dyax she oversaw successful commercialization of kalbiter® ecalantide the first subcutaneous treatment approved in the us for treatment of acute attacks of hereditary angioedema a life threatening orphan disease dr magovcevicliebisch was also instrumental in establishing dyaxs licensing and funded research programs lfrp based on its proprietary phase display technology which has been successfully licensed to over  licenses and collaborators and has generated numerous clinical stage candidates and two approved products prior to dyax dr magovcevicliebisch was director of intellectual property and patent counsel for transkaryotic therapies inc cambridge ma she received her jd from suffolk university law school and her phd in genetics from harvard university agtc has developed a novel and proprietary aav manufacturing system that can be broadly applied to developing innovative therapies for genetic eye diseases as well as many conditions that result from single gene mutations said dr magovcevicliebisch  i am pleased to have the opportunity to collaborate with my fellow directors to ensure that agtc leverages its products processes and platforms to create value for both agtcs shareholders and patients the company also announced that two current members of its board of directors jill carroll a class ii director and dr sam wu a class i director have notified the board of their intentions to rotate off the board at the companys next board meeting which will take place in july consistent with policies of the venture investment firms with which they are affiliated we thank jill and sam for their valuable service to agtc said dr koenig and we look forward to their continued contributions and counsel during their remaining tenure as directorsabout agtc agtc is a clinicalstage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology agtcs lead product candidates which are each in the preclinical stage focus on xlinked retinoschisis achromatopsia and xlinked retinitis pigmentosa which are rare diseases of the eye caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments for additional information visit wwwagtccomforward looking statements statements in this press release should be read in conjunction with the companys registration statement on form s file no  as amended filed with the sec in addition to historical financial information the following discussion contains forwardlooking statements that reflect the companys plans estimates assumptions and beliefs actual results could differ materially from those discussed in the forwardlooking statements forwardlooking statements include information concerning possible or assumed future results of operations business strategies and operations preclinical and clinical product development and regulatory progress financing plans potential growth opportunities potential market opportunities and the effects of competition forwardlooking statements include all statements that are not historical facts and can be identified by terms such as anticipates believes could seeks estimates expects intends may plans potential predicts projects should will would or similar expressions and the negatives of those terms given these uncertainties you should not place undue reliance on these forwardlooking statements also forwardlooking statements represent managements plans estimates assumptions and beliefs only as of the date of this release except as required by law we assume no obligation to update these forwardlooking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forwardlooking statements even if new information becomes available in the futurecontact david carey lazar partners ltd t   dcareylazarpartnerscom corporate contact larry bullock chief financial officer applied genetic technologies corporation t   lbullockagtccom axcella announces the appointment of ivana magovcevicliebisch phd jd as executive vice president chief strategy and corporate development officer  business wire axcella announces the appointment of ivana magovcevicliebisch phd jd as executive vice president chief strategy and corporate development officer may    am eastern daylight time cambridge massbusiness wireaxcella a biotechnology company pioneering transformative amino acidbased therapeutics for a range of severe diseases announced today that ivana magovcevicliebisch phd jd has joined the company as executive vice president chief strategy and corporate development officer she comes to axcella with nearly two decades of senior management experience and will oversee business strategy and development as well as all corporate legal activities including intellectual property and commercial planning efforts “axcella’s drug development approach represents a unique opportunity to unlock the full potential of amino acid therapeutics” said dr magovcevicliebisch “i feel privileged to be part of axcella’s growing team and look forward to building on its promising science and establishing new complementary partnerships” “we are thrilled to welcome ivana to axcella’s senior leadership team she brings an exceptional combination of extensive expertise in business development drug commercialization intellectual property and corporate strategy making her a critical addition to our senior leadership team as we move into latestage development and commercialization” added robert connelly president and chief executive officer of axcella before joining axcella dr magovcevicliebisch was senior vice president and head of global business development at teva pharmaceutical industries ltd where she led and executed over  billion in business development transactions ranging from licensing to the acquisition of drug candidates commercial products and companies she previously worked at dyax corp for a dozen years in management roles of increasing scope and responsibility including executive vice president and chief operating officer while at dyax dr magovcevicliebisch established the commercial infrastructure of the company’s first fdaapproved drug kalbitor® for treatment of hereditary angioedema attacks she began her career as director of intellectual property and patent counsel at transkaryotic therapies inc dr magovcevicliebisch is currently a director on the boards of biotech companies applied genetic technologies corporation agtc and alivio therapeutics she is also a trustee of the wentworth institute of technology and an overseer of the boston ballet boston museum of science and beth israel deaconess medical center she holds a phd in genetics from harvard university and a jd in high technology law from suffolk university law school about axcellaaxcella is pioneering revolutionary amino acidbased therapeutics as powerful signaling molecules with broad mechanisms of action applicable to a range of severe diseases amino acids critically and uniquely regulate a wealth of essential disease pathways and biologies leveraging its unique platform axcella seeks to transform the traditional drug discovery process by significantly accelerating the speed of candidate generation to clinical validation within months the company has translated its discoveries into compounds that have been tested in multiple clinical studies to date with lead programs in nafldnash intractable epilepsies and atrophic diseases and a rich pipeline of drugs for rare genetic diseases axcella was founded by flagship venturelabs and has received financing from flagship pioneering alongside coinvestors fidelity research  management group gurnet point capital and nestlé health science axcella is based in cambridge mass for more information visit wwwaxcellahealthcom contacts media contactten bridge communicationsdan quinn dantenbridgecommunicationscomorcompany contactaxcella healththomas leggett tleggettaxcellahealthcom release summary axcella announced today that ivana magovcevicliebisch phd jd has joined the company as executive vice president chief strategy and corporate development officer contacts media contactten bridge communicationsdan quinn dantenbridgecommunicationscomorcompany contactaxcella healththomas leggett tleggettaxcellahealthcom search advanced news search advanced news search log in sign up board of directors agtc youtube linkedin facebook twitter board of directors led by the best scott koenig dr koenig has been president and chief executive officer of macrogenics sinceseptember   he is chairman of the board of directors at applied genetic technologies corporation agtc and at the children’s research institute cri of children’s national medical center and serves as a board member of macrogenics the biotechnology industry organization bio children’s national medical center and is a member of the cornell university council  prior to joining macrogenics he served as senior vice president of research at medimmune inc where he participated in the selection and maturation of the companys product pipeline for  years from  to  he worked in the laboratory of immunoregulation at the national institute of allergy and infectious diseases niaid at the national institutes of health nih where he investigated the immune response to retroviruses and studied the pathogenesis of aids dr koenig received his ab and phd from cornell university and his md from the university of texas health science center in houston where he was elected to alpha omega alpha  he completed his residency in internal medicine at the hospital of the university of pennsylvania and is board certified in internal medicine and allergy and immunology david guyer dr guyer is cofounder chief executive officer and chairman of the board of ophthotech corporation he has significant medical drug development and commercial experience in ophthalmology prior to joining ophthotech dr guyer worked as a venture capitalist and partner at sv life sciences following a successful career in academic medicine as professor and chairman of the department of ophthalmology at new york university school of medicine dr guyer cofounded and served as ceo and director at eyetech pharmaceuticals inc where he led the company through private public and corporate financings over  million including a  million ipo offering he has served on the board of directors for many public and private companies dr guyer graduated summa cum laude from yale college receiving his bachelor of science degree and earned his medical degree from the johns hopkins university school of medicine he completed his ophthalmology residency at the wilmer ophthalmological institute at johns hopkins hospital and a retinal fellowship at the massachusetts eye and ear infirmary at harvard medical school ed hurwitz ed is a director with alta partners and managing director of precision bioventures llc  in addition to agtc he currently serves on the board of directors of macrogenics and viewpoint therapeutics  ed also led alta’s investments in avid radiopharmaceuticals calistoga pharmaceuticals cara therapeutics  chemocentryx foldrx pharmaceuticals sunesis pharmaceuticals taligen therapeutics threshold pharmaceuticals and zafgen prior to joining alta ed served as senior vice president and cfo of affymetrix from  to  from  to  ed was a biotechnology research analyst for robertson stephens  company and from  to  was a biotechnology research analyst for smith barney shearson from  to  ed practiced commercial law at cooley godward llp ed earned his juris doctor and master of business administration degrees in  from the university of california berkeley’s boalt school of law and haas school of business respectively ed earned a bachelor of arts in molecular biology from cornell university in  ivana magovcevicliebisch dr magovcevicliebisch joined teva as senior vice president head of global business development in april  in this capacity she is responsible for the execution of transactions identified by teva’s rd global franchises and us specialty teams including the licensing andor acquisition of commercial products drug candidates and technologies prior to teva dr magovcevicliebisch joined dyax corp in april  and had served as an executive officer at the company since  during her tenure she held several senior positions within the company most recently as executive vice president and chief operating officer prior to dyax dr magovcevicliebisch was director of intellectual property and patent counsel for transkaryotic therapies inc cambridge ma dr magovcevicliebisch received her juris doctor in high technology law from suffolk university law school boston ma and her doctor of philosophy in genetics from harvard university cambridge ma arnie oronsky dr arnold l oronsky has been a general partner at interwest since  he was formerly vice president for discovery research for the lederle laboratories division of american cyanamid company where he directed all of the research for new drugs and supervised approximately three hundred employees dr oronsky holds a phd in immunology from columbia university and has published over  scientific articles in addition to being a senior partner at interwest he also serves as a senior lecturer in the department of medicine at johns hopkins medical school dr oronsky serves as a director on the boards of several life science corporations anne vanlent anne m vanlent is currently the president of amv advisors an advisory firm which she founded in  to provide corporate strategy and financial consulting services to emerging growth life sciences companies she currently serves as a director of and chair of the audit committee of ocera therapeutics inc a director member of the audit committee and member of the compliance committee of novelion pharmaceuticals inc previously aegerion pharmaceuticals inc   and as lead independent director and audit chair of aviragen pharmaceuticals inc formerly biota all nasdaq listed companies  from may  through april  ms vanlent was the executive vice president and chief financial officer of barrier therapeutics inc a nasdaq company that developed and marketed prescription dermatology products that was acquired by stiefel laboratories in august  from july  to october  she was the executive vice president – portfolio management for sarnoff corporation a multidisciplinary research and development firm  from  to  she served as the senior vice president and chief financial officer of the liposome company inc a publiclytraded biopharmaceutical company she served as a director chair of the audit committee and member of the compensation committee of onconova therapeutics from july  to may  and as director of integra life sciences holding corporation nasdaqgs iart from  to may  and chaired its audit committee from  until  she also served as a director and chair of the audit committee of penwest pharmaceuticals a nasdaqlisted company from  through its sale to endo pharmaceuticals inc in the fall of   ms vanlent received a ba degree in physics from mount holyoke college   james rosen jimmy rosen is a partner on intersouth’s life sciences investment team  he began with the firm as an intern in  while pursuing his graduate degrees joined fulltime in  and became a partner in   prior to joining intersouth he spent  years in clinical research and financial positions in the health care and biotechnology sectors jimmy’s research experience includes programs at the lineberger comprehensive cancer center at uncchapel hill the national cancer institute duke university medical center and its comprehensive cancer center  he also managed and monitored clinical trials at a privately held contract research organization which led to fdaapproved products  jimmy spent several years as an equity research analyst at brean murray  co covering biopharmaceuticals genomics generics drug delivery and medical device companies  prior to his research and wall street functions he spent five years in emergency medical services as a mountain search  rescue and ambulance medic jimmy currently serves on numerous boards and advisory committees including the public health foundation board and dean’s advisory council for the gillings school of global public health at the university of north carolina the board of visitors for north carolina central university the board of florida bio and the oversight committee for the dukecoulter translational partners program  he is also a frequent lecturer at duke unc and nc state university jimmy holds a ba from duke university and an mba from uncchapel hill’s kenanflagler school of business where he was a carolina venture fellow and recipient of the frank hawkins kenan award for excellence  he received his msph from the unc school of public health where his thesis focused on the relationship between technology transfer in biotechnology and venture capital investment  in  jimmy was awarded the eisenhower fellowship for which he designed and executed a program to evaluate the prospects for health care innovation in china and southeast asia sue washer an experienced entrepreneur with a strong scientific and operational background sue brings a decade of experience in pharmaceutical management and research with abbott labs and eli lilly  company and more than  years of senior management experience with entrepreneurial firms in florida including three startups at agtc sue has successfully secured investments of more than  million from nationally recognized venture capitalists and granting agencies negotiated and closed on a major collaboration with a top five biotech company lead the company to complete critical milestones and recruited an experienced management team her experience as a group leader with abbott’s diagnostic division helped hone her skills in bringing new products and technologies from the lab bench into the market place sue sits on the board of the university of florida’s center for entrepreneurship bioflorida southeast bio gainesville area chamber of commerce gainesville area innovation network and the florida high tech corridor council she has a degree in biochemistry from michigan state university and an mba from the university of florida where she was one of the first graduates from the warrington college of business entrepreneurship program about us our teamboard of directors scientific advisors  foundersophthalmology scientific advisory boardotology scientific advisory board careers and internships contact us alachua – headquarters  nw th terrace suite  alachua florida   map cambridge one kendall square w suite b cambridge ma   map name  email  comments or questions security code please enter the letters from the image below in order to prevent spam  copyright     agtc    social media disclaimer axcella announces the appointment of ivana magovcevicliebisch phd jd as executive vice president chief strategy and corporate development officer  axcella health inc  skip to main content menu search this site what we dowhy amino acidsour platformtherapeutic focuswho we areleadership teamboard of directorsadvisorsinvestorspress releases  eventsjoin uscareer opportunities   axcella announces the appointment of ivana magovcevicliebisch phd jd as executive vice president chief strategy and corporate development officer cambridge mass may   – axcella a biotechnology company pioneering transformative amino acidbased therapeutics for a range of severe diseases announced today that ivana magovcevicliebisch phd jd has joined the company as executive vice president chief strategy and corporate development officer she comes to axcella with nearly two decades of senior management experience and will oversee business strategy and development as well as all corporate legal activities including intellectual property and commercial planning efforts“axcella’s drug development approach represents a unique opportunity to unlock the full potential of amino acid therapeutics” said dr magovcevicliebisch “i feel privileged to be part of axcella’s growing team and look forward to building on its promising science and establishing new complementary partnerships”“we are thrilled to welcome ivana to axcella’s senior leadership team she brings an exceptional combination of extensive expertise in business development drug commercialization intellectual property and corporate strategy making her a critical addition to our senior leadership team as we move into latestage development and commercialization” added robert connelly president and chief executive officer of axcellabefore joining axcella dr magovcevicliebisch was senior vice president and head of global business development at teva pharmaceutical industries ltd where she led and executed over  billion in business development transactions ranging from licensing to the acquisition of drug candidates commercial products and companies she previously worked at dyax corp for a dozen years in management roles of increasing scope and responsibility including executive vice president and chief operating officer while at dyax dr magovcevicliebisch established the commercial infrastructure of the company’s first fdaapproved drug kalbitor® for treatment of hereditary angioedema attacks she began her career as director of intellectual property and patent counsel at transkaryotic therapies incdr magovcevicliebisch is currently a director on the boards of biotech companies applied genetic technologies corporation agtc and alivio therapeutics she is also a trustee of the wentworth institute of technology and an overseer of the boston ballet boston museum of science and beth israel deaconess medical center she holds a phd in genetics from harvard university and a jd in high technology law from suffolk university law schoolabout axcella axcella is pioneering revolutionary amino acidbased therapeutics as powerful signaling molecules with broad mechanisms of action applicable to a range of severe diseases amino acids critically and uniquely regulate a wealth of essential disease pathways and biologies leveraging its unique platform axcella seeks to transform the traditional drug discovery process by significantly accelerating the speed of candidate generation to clinical validation within months the company has translated its discoveries into compounds that have been tested in multiple clinical studies to date with lead programs in nafldnash intractable epilepsies and atrophic diseases and a rich pipeline of drugs for rare genetic diseases axcella was founded by flagship venturelabs and has received financing from flagship pioneering alongside coinvestors fidelity research  management group gurnet point capital and nestlé health science axcella is based in cambridge mass for more information visit wwwaxcellahealthcom contact us  memorial drive cambridge ma entrance on blackstone street  third flooro   f infoaxcellahealthcom linkedin site mapterms of useprivacy policy   axcella health inc all rights reserved